Pitavastatin

Description

Introducing PharmAlliance International Labs’ Pitavastatin Tablets

Company Introduction:

Welcome to PharmAlliance International Labs Private Limited, a pioneering provider of innovative pharmaceutical solutions dedicated to enhancing patient health and well-being. We are delighted to introduce our flagship product, Pitavastatin Tablets, meticulously crafted to effectively manage lipid disorders and reduce the risk of cardiovascular events.

Drug Classification:

Pitavastatin belongs to the class of medications known as statins, or HMG-CoA reductase inhibitors. This class of drugs works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol synthesis in the liver. By lowering cholesterol levels in the blood, Pitavastatin helps reduce the risk of cardiovascular diseases.

Formulations:

PharmAlliance International Labs offers Pitavastatin Tablets in various strengths, including 1mg, 2mg, 3mg, and 4mg formulations. These oral tablets are packaged in blister packs containing 10 tablets each, ensuring convenient administration.

Indications:

Pitavastatin Tablets are indicated for:

Lowering elevated levels of total cholesterol, LDL cholesterol, apolipoprotein B, and triglycerides in the blood.

Increasing levels of HDL cholesterol in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia.

Reducing the risk of cardiovascular events such as myocardial infarction, stroke, revascularization procedures, and cardiovascular mortality in patients with established cardiovascular disease or at high risk for cardiovascular events.

Usage:

Pitavastatin Tablets should be taken orally once daily, with or without food. It is important to adhere to the prescribed dosage and administration instructions provided by a healthcare professional. Regular monitoring of lipid levels and liver function tests is recommended during treatment with Pitavastatin to assess treatment response and detect any potential adverse effects.

Dosage:

The recommended starting dose of Pitavastatin is typically 2mg once daily. Dosage adjustments may be made based on the patient’s lipid profile, cardiovascular risk factors, and response to treatment. The maximum recommended dose of Pitavastatin is 4mg once daily for most patients.

Pharmacokinetics:

Pitavastatin is well absorbed from the gastrointestinal tract and undergoes extensive hepatic metabolism. The primary route of elimination is via the bile, with minimal renal excretion. Pitavastatin exhibits a relatively long half-life, allowing for once-daily dosing and sustained lipid-lowering effects.

Pharmacodynamics:

By inhibiting HMG-CoA reductase, Pitavastatin effectively lowers LDL cholesterol levels, the primary target for cardiovascular risk reduction. Pitavastatin also modestly increases HDL cholesterol levels and reduces triglyceride levels, further contributing to its cardiovascular protective effects.

Side Effects:

Common side effects associated with Pitavastatin therapy may include headache, myalgia (muscle pain), abdominal pain, constipation, and nausea. Rare but serious adverse effects such as myopathy (muscle damage), rhabdomyolysis (severe muscle breakdown), and hepatotoxicity (liver damage) may occur and require medical attention.

Experience the superior efficacy and cardiovascular benefits of PharmAlliance International Labs’ Pitavastatin Tablets. For more information, please contact us. We are committed to promoting heart health and enhancing patient well-being through our pharmaceutical products.